The Assessment of a Weight-Gain Agent for the Treatment of Olanzapine-Associated Anti-Obesity Agent in Patients With Schizophrenia, Schizophreniform Disorder, Schizoaffective Disorder, and Bipolar I Disorder
This study has been completed.
Study NCT00044187
Information provided by Eli Lilly and Company
First Received: August 21, 2002
Last Updated: July 18, 2006
History of Changes
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
